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Projections for nanomedicine into the next decade: But is it all about 
pharmaceuticals?
It is clear that many “think tanks” have projected high growth for nanomedicine in the 
coming decades (Visiongain 2006). But ask yourself this question: In what commercial 
areas will nanomedicine make the largest impact? Are there any hidden nanomedicine 
technologies yet untapped? Most people following this ﬁ  eld will say pharmaceuticals 
(or the more effective delivery of drugs) will constitute the largest commercial growth 
and the most revenues in nanomedicine for the next decade. However, please do not 
forget the impact that nanomaterials are having on redesigning biomedical devices 
used for imagining and diagnostics (simultaneously), tissue reconstruction, molecular 
assembly (for which many believe is the “Holy Grail” of nanomedicine), high resolu-
tion microscopy, nanopores to detect single molecules, immunohistochemistry, DNA 
detection, RNA-based drug delivery, lab-on-a-chip incorporating micro and nanoﬂ  uid-
ics, nanobiosensors, and the list goes on. 
One particularly high impact area in the above list that does not seem to attract 
as much attention (as of yet) is the use of nanomedicine in tissue reconstruction. 
Clearly, the implant market for returning function to damaged or diseased tissues is 
large and will only become larger as high percentages of people will be entering their 
elderly years in the coming decade and want to remain active. With implant lifetimes 
(such as the hip implant, the most commonly replaced joint) less than 10–15 years, 
it is clear that such devices need help. As the US (via the US National Nanotechnol-
ogy Initiative), European, and Japanese governments are leading public investors in 
nanotechnology today (US and Japan are the ﬁ  rst and second largest supporters of 
nanomedicine government funding worldwide [Visiongain 2006]), much of these 
funds are going exactly to nanotechnologies that can improve the function of numer-
ous implantable devices. 
However, a forgotten investor in nanomedicine-related research that is integral in 
the tissue reconstruction arena are venture capitalists who supply seed funds to promote 
the translation of “bench-top” research to a “real” commercial product. Nanomedicine 
receives an estimated 40% of its funding from private investment (Visiongain 2006). 
Thus, while government funding is important, private funds to translate such research 
to commercial sectors are equally as important and play an extremely large role in 
creating better tissue constructs from nanotechnology.
There are daily exciting reports on the use of various nanostructured materials that 
can regenerate bone, vascular, bladder, nervous system, cartilage, muscle, skin, etc., 
tissues more effectively than what we are using today. While much work is needed (ie, 
few conclusive toxicological studies have been performed on nanomaterials and some 
believe that certain nanoparticles may cause pulmonary damage), when compared with 
the pharmaceutical industry, nanomedicine research in tissue reconstruction is more 
open and publicly reported. Since public relations and public support of new technolo-
gies is critical for continued government of private funding in nanomedicine, this may 
suggest that the use of nanotechnology to improve today’s implants may become one 
of the strongest commercial sectors in all of nanomedicine in the coming decade. 
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